Heparin-bonded stent-graft for the treatment of tasc ii c and d femoropopliteal lesions: The viabahn-25 cm trial

Journal of Endovascular Therapy

Volumn 21, Issue 6, 2014, Pages 765-774

  Zeller, Thomas ^a   Peeters, Patrick ^b   Bosiers, Marc ^c   Lammer, Johannes ^d   Brechtel, Klaus ^e   Scheinert, Dierk ^f   Rastan, Aljoscha ^a   Noory, Elias ^a   Beschorner, Ulrich ^g  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b IMELDA HOSPITAL   (Belgium)

^c Hospital Sint Blasius   (Belgium)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f Park Krankenhaus   (Germany)

^g CoreLab Bad Krozingen ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; ANTICOAGULANT AGENT; BIOMATERIAL;

ADULT; AGED; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTERY PROSTHESIS; ARTICLE; CLAUDICATION; DEVICE SAFETY; ENDOPROSTHESIS; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; POPLITEAL ARTERY; PROSPECTIVE STUDY; RESTENOSIS; SUPERFICIAL FEMORAL ARTERY; ADVERSE EFFECTS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; CLINICAL TRIAL; DEVICES; ENDOVASCULAR SURGERY; EUROPE; FEMORAL ARTERY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POSTOPERATIVE COMPLICATIONS; PROSTHESIS; STENOSIS, OCCLUSION AND OBSTRUCTION; STENT; TIME; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; ANKLE BRACHIAL INDEX; ANTICOAGULANTS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; ENDOVASCULAR PROCEDURES; EUROPE; FEMALE; FEMORAL ARTERY; HEPARIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; STENTS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84914173303     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/14-4790R.1     Document Type: Article

References (26)

1. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510-551
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324
3. White C. Intermittent claudication. N Engl J Med. 2007;356:1241-1250
4. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75
5. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2011;32: 2851-2906
6. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/ AHA 2005 practice guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113;e463-e465
7. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888
8. Laird JR, Katzen BT, Scheinert D, et al; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-76
9. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699
10. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365
11. Werk M, Albrecht T, Meyer DR, et al. Paclitaxelcoated balloons reduce restenosis after femoropopliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831-840
12. Scheinert D, Duda S, Zeller T, et al. LEVANT-1 trial for femoropopliteal revascularization: First-in-human randomized trial of low dose drug-coated balloon vs. uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10-9
13. Dake MD, Ansel GM, Jaff MR, et al; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2010;4:495-504
14. Beschorner U, Sixt S, Schwarzwälder U, et al. Recanalization of chronic occlusions of the superficial femoral artery using the Outback re-entry catheter: a single centre experience. Cath Cardiovasc Intervent. 2009, 74:934-938
15. Kougias P, Chen A, Cagiannos C, et al. Subintimal placement of covered stent versus subintimal balloon angioplasty in the treatment of long-segment superficial femoral artery occlusion. Am J Surg. 2009;198:645-649
16. Bosiers M, Deloose K, Callaert J, et al. Results of the Protege EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042-50
17. Bosiers M, Peeters P, Tessarek J, et al. The Zilver PTX Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54:115-122
18. Lammer J, Zeller T, Hausegger K, et al. Heparin-bonded covered stents versus bare metal stents for symptomatic peripheral arterial disease: the VIASTAR trial. J Am Coll Cardiol. 2013;62:1320-1327
19. Mohler ER, Gornik HL, Gerhard-Herman M, et al. 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing. Part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation appropriate use criteria task force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Am Coll Cardiol. 2012;60:242-276
20. Kuhan G, Abisi S, Braithwaite BD, et al. Early results with the use of heparin-bonded stent graft to rescue failed angioplasty of chronic femoropopliteal occlusive lesions: TASC D lesions have a poor outcome. Cardiovasc Intervent Radiol. 2012;35:1023-8
21. Saxon RR, Chervu A, Jones PA, et al. Heparinbonded, expanded polytetrafluoroethylenelined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013;24:165-173
22. Zeller T, Rastan A, Macharzina R, et al. Drugcoated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J Endovasc Ther. 2014;21:359-368
23. Siracuse JJ, Giles KA, Pomposelli FB, et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg. 2012;55:1001-1007
24. Pedersen G, Laxdal E, Ellensen V, et al. Improved patency and reduced intimal hyperplasia in PTFE grafts with luminal immobilized heparin compared with standard PTFE grafts at six months in a sheep model. J Cardiovasc Surg (Torino). 2010;51:443-448
25. Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian Propaten trial-1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses-A randomised clinical controlled multi-centre trial. Eur J Vasc Endovasc Surg. 2011;41:668-673
26. Smouse HB, Nikanorov A. LaFlash D. Biomechanical forces in the femoropopliteal arterial segment. What happens during extremity movement and what is the effect on stenting? Endovascular Today. 2005;4:60-66.